FRIENDS OF JAMES ANNUAL REPORT 2025



Friends of James

MESSAGE FROM THE PRESIDENT



Dear FOJ Community,

2025 was a milestone year for our family and for Friends of James Inc. On a personal note, Anthony and I welcomed our third child, Brooks, into our lives. Because our hands and hearts were especially full adjusting to life as a family of five, we took a deliberate pause from hosting a major fundraising event this year. Even without a formal gathering, we are profoundly grateful for the continued generosity of our donors who stepped up to support our mission throughout the year.

Despite a quieter calendar on the event front, our advocacy and impact remained strong. In March, I had the privilege of traveling to Washington, D.C., alongside fellow Angelman Syndrome advocates to lobby on Capitol Hill for critical rare disease initiatives, meeting with the offices of both New Jersey senators and three New Jersey House members. In November, Anthony and I attended the Foundation for Angelman Syndrome Therapeutics (FAST) Summit and Gala in Orlando, where we proudly presented a $15,000 donation on behalf of Friends of James—bringing our cumulative giving to FAST to $135,000 since 2022.

With one therapeutic candidate having entered Phase 3 clinical trials and many more advancing through the pipeline, there has never been a more hopeful time for the Angelman Syndrome community. We closed 2025 in a strong financial position, ensuring we are well-prepared to accelerate our fundraising, community outreach, and support for life-changing research in 2026. Thank you for walking alongside James and our entire family on this journey.

Warmly,

Kathryn Poerio ("Katie")

President

MISSION STATEMENT & FUNDING PHILOSOPHY

Friends of James aims to increase awareness of Angelman Syndrome, fund research to advance therapies for treating the disorder and support local initiatives serving people with special needs.

There are currently several treatments for Angelman Syndrome that are progressing through clinical trials and many more in the pipeline. We will continue to donate a large portion of funds toward research until treatment options are available for those with Angelman Syndrome. At that time, we will shift our focus towards other initiatives to support people living with disabilities by giving them resources to thrive in the community.

2025 HIGHLIGHTS





- Katie joined a group of Angelman Syndrome advocates in Washington, D.C. in March to lobby for specific initiatives related to AS and rare disease. She spent the day meeting with the offices of both NJ senators and three NJ house members. Read more about the success of our inaugural year visiting the Hill here
- Katie and Anthony attended the FAST (Foundation for Angelman Syndrome Therapeutics) Summit and Gala in Orlando, Fl in Nov and proudly donated $15,000 on behalf of Friends of James

FAST is the leading patient advocacy organization working to cure Angelman syndrome.

As the largest non-governmental funder of Angelman syndrome research in the world, FAST's goal is to drive forward transformative research and development programs as quickly as possible for those living with Angelman syndrome—regardless of age or genotype.

MONEY IN ACTION


Friends of James proudly donated $15,000 to FAST in 2025. In total, we have raised $135,000 in funds donated directly to FAST (2022-2025).

FAST is deeply invested in bringing promising interventions into current medical practice, as safely and quickly as possible. To this end, FAST is driving translational research and supporting the advancement of therapeutics for animal models to humans living with Angelman syndrome.

The results are incredibly promising, and the Angelman Syndrome community looks forward to seeing progress in the chart on the following page each year. This chart shows the drug development pipeline as FAST aggressively pursues multiple treatment options

Angelman Syndrome Drug Development Pipeline

Hover over an approach for more information, or click on the progress of a particular program to read more.



BOARD MEMBERS



Kathryn Poerio
President



Anthony Poerio
Secretary & Treasurer



Sarah Ambrosino
Director



Lauren Cochran
Director



Erin Falco
Director



Tom Trapani
Director

THANK YOU DONORS

Platinum - $10,000+

Johnson & Johnson Technology

Gold - $5,000+

Fred & Ellen Gentzel
Maureen & Frank Poerio

Silver – 1,000+

Kathi & Bill Macholz
Greg Arnold

Bronze – 500+

Russell Indemaio
Jeannette Cowen
Stan & Linda Lahoda

FINANCIAL BREAKDOWN

STATEMENT OF FINANCIAL POSITION AS OF DECEMBER 31, 2025

Current Assets:	2025
Cash & Cash Equivalents	23,631
Investments	11,972
Total Current Assets	35,603

Property & Equipment	2025
Office	0
Computer Hardware	0
Software	0
Website	0
Total Property & Equipment	0

TOTAL ASSETS: 35,603

Current Liabilities	2025
Accounts Payable	42
Accounts	0
Total Current Liabilities	42

Net Assets	2025
Open Equity Balance	11,799
Stocks / ETF's	-8,826
Retained Earnings	25,966
Net Income	6,623

TOTAL LIABILITIES & NET ASSETS: 35,603

FINANCIAL BREAKDOWN

PUBLIC SUPPORT & FUNCTIONAL EXPENSES

Public Support & Revenue	2025
Contributions	26,485
Net Investment Return	0
Total Revenue	26,485

TOTAL PUBLIC SUPPORT & REVENUE: 26,485

Functional Expenses	2025
Management & General	1,198
Fundraising	480
Contributions*	18,185
Total Expenses	19,862

TOTAL FUNCTIONAL EXPENSES: 6,623

NET ASSETS

Equity	2025
Change in Net Assets	9,620
Net Assets, beginning of year	25,983
Net Assets, end of year	35,603



Friends of James

Thank you!

Join Our Community

© 2026 Friends of James Inc. All Rights Reserved.